Rebamipide, an amino acid derivative of 2-(1H)-quinolinone, is used for mucosal protection,[1] healing of gastroduodenal ulcers, and treatment of gastritis.[2] It works by enhancing mucosal defense, scavenging free radicals,[3] and temporarily activating genes encoding cyclooxygenase-2.[4] Rebamipide is used in a number of Asian countries including Japan (marketed as Mucosta), South Korea, China[5] and India (where it is marketed under the trade name Rebagen). It is also approved in Russia under the brand name Rebagit.[6] It is not approved by the Food and Drug Administration for use in the United States. Studies have shown that rebamipide can fight the damaging effects of NSAIDs on the GIT mucosa,[7] and more recently, the small intestine, but not for naproxen-induced gastric damage.[8] It has also been studied for the treatment of Beh├žet's disease.[9] It was shown to successfully treat pouchitis in a single-N study after first-line therapies for the condition were unsuccessful.[10] Some studies have shown effectiveness in presbyacusis (age-related hearing loss).[11] It has also been shown to alleviate signs and symptoms of dry eyes in a randomized controlled trial although this is not yet widely available clinically.[12]